Table 1.
Patient characteristics
| Patient | Sex | Age | MS course | Disease duration (years) | EDSS | Pretreatment LVEF before treatment (%) | Dose per infusion (mg/m2) | Cumulative MITOX dose (mg) | LVEF after MITOX (%) | Follow-up LVEF (%) |
| 1 | M | 37 | SPMS | 2 | 6.0 | 64 | 12 | 20.9 | 48 | 60 |
| 2 | F | 43 | SPMS | 6 | 5.5 | 66 | 12 | 17.7 | 54 | 71 |
| 3 | M | 30 | SPMS | 12 | 5.5 | 65 | 12 | 46.2 | 52 | 63/61 |
| 4 | M | 35 | SPMS | 3 | 5.5 | 64 | 12 | 51.4 | 49 | 64/60 |
EDSS, Expanded Disability Status Scale; F, female; LVEF, left ventricular ejection fraction; M, male; MITOX, mitoxantrone; MS, multiple sclerosis; SPMS, secondary progressive multiple sclerosis.